Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Share-based Compensation for 18 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 5.26% year-over-year to $40.0 million; the trailing twelve-month figure through Jun 2026 stood at $168.0 million (up 24.44% YoY), and the FY2025 full-year result was $157.0 million, up 27.64% from the prior year.
• Share-based Compensation eased to $40.0 million in Q2 2026 per TEVA's latest filing, from $43.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $51.0 million in Q4 2025 and bottomed at $24.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $33.8 million across 5 years, with a median of $33.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation dropped 23.08% in 2023, then surged 50.0% in 2025.
• Over 5 years, Share-based Compensation stood at $36.0 million in 2022, then dropped by 22.22% to $28.0 million in 2023, then advanced by 21.43% to $34.0 million in 2024, then soared by 50.0% to $51.0 million in 2025, then decreased by 21.57% to $40.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $40.0 million, $43.0 million, and $51.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.